PrimeRFP SCOUT · Federal Contract Recompete Brief

W911SR26CA003SBIR purpose THIS SMALL business — Cygnos Biotech, LLC

Cygnos Biotech, LLC holds $1.6M across 2 federal awards, concentrated at Department of Defense (DOD). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: SBA. Recompete timing centers on the Aug 1, 2027 PoP end — agencies typically plan 12–18 months ahead.

W6qk Acc-Apg

Awarding office

Cygnos Biotech, LLC

Recipient

Aug 1, 2027

PoP end

$1.4M

Obligated

$1.4M

Potential

541714

NAICS

AC12

PSC

SBA

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Cygnos Biotech, LLC — $90

Contract facts

SBA

Contract numberW911SR26CA003

AgencyW6qk Acc-Apg

Awarding officeW6qk Acc-Apg

Awarding agencyDepartment of Defense (DOD)

Funding agencyDepartment of Defense (DOD)

IncumbentCygnos Biotech, LLC

CAGE8WQ76

UEIPXYDY5CQJDM3

NAICS541714

No full NAICS 541714 intel page yet. Browse NAICS intelligence

PSCAC12

Place of performanceMIAMI FL

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition After Exclusion Of Sources

PoP startFeb 2, 2026

PoP end (current)Aug 1, 2027

Obligated$1.4M

Current value$1.4M

Potential value$1.4M

THE PURPOSE OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II CONTRACT IS TO SHOW EFFICACY OF ANTI-VIRAL TREATMENT WITH THE PVX THERAPEUTIC. is a federal SBA award for W6qk Acc-Apg held by Cygnos Biotech, LLC. Estimated value $1.4M ($1.4M obligated). Current period of performance ends Aug 1, 2027. Last award drew 1 bidder. Place of performance: MIAMI FL.

THE PURPOSE OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II CONTRACT IS TO SHOW EFFICACY OF ANTI-VIRAL TREATMENT WITH THE PVX THERAPEUTIC.

Recompete timing

Public

● Expiring in 328 days

Current PoP ends Aug 1, 2027 (328 days remaining). Agencies typically plan 12–18 months ahead — at 10.8 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Cygnos Biotech, LLC — $1.6M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)

Department of Defense (DOD)$1.6M · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract W911SR26CA003?

W911SR26CA003 (SBIR purpose THIS SMALL business) is a W6qk Acc-Apg award with a potential value of $1.4M, currently held by Cygnos Biotech, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded W911SR26CA003?

W6qk Acc-Apg awarded W911SR26CA003 to Cygnos Biotech, LLC (potential $1.4M).

Who is the incumbent on W911SR26CA003?

Cygnos Biotech, LLC is the incumbent with $1.6M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Aug 1, 2027.

When does Cygnos Biotech, LLC’s W911SR26CA003 come up for recompete?

SCOUT tracks a period-of-performance end of Aug 1, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on W911SR26CA003 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jul 1, 2026 · refreshed monthlyLatest procurement action Jan 30, 2026